Bevacizumab
Treatment for Macular Degeneration
Typical Dosage: 1.25 mg intravitreal injection every 4-8 weeks
Effectiveness
88%
Safety Score
45%
Clinical Trials
130
Participants
55K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
1.25 mg intravitreal injection every 4-8 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$1,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$2,010.87
Active Clinical Trials
1 active trial recruiting for Bevacizumab in Macular Degeneration
Aflibercept and Bevacizumab for Diabetic Maculopathies
NCT06850571RECRUITINGPHASE4
102 participants
INTERVENTIONAL
Baghdad, Iraq
Started: Feb 20, 2025
Completed Clinical Trials
14 completed trials for Bevacizumab in Macular Degeneration
Systemic Avastin Therapy in Age-Related Macular Degeneration
NCT00531024COMPLETEDPHASE2, PHASE3
30 participants
INTERVENTIONAL
Vienna, Austria
Started: Aug 1, 2005
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
NCT04138420COMPLETED
38 participants
OBSERVATIONAL
Naples, Italy
Started: Jan 25, 2017
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT01327222COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Milan, Italy
Started: Feb 1, 2011
VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
NCT00727753COMPLETED
54 participants
OBSERVATIONAL
Zurich, Switzerland
Started: Jul 1, 2008
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT06190093COMPLETEDPHASE3
400 participants
INTERVENTIONAL
Arcadia, United States +60 more
Started: Jan 24, 2024
Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
NCT00359164COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Vancouver, Canada
Started: Jul 1, 2006
Combination Therapy for Age-Related Macular Degeneration.
NCT00376701COMPLETEDPHASE2
103 participants
INTERVENTIONAL
Edmonton, Canada +4 more
Started: Sep 1, 2006
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT03744806COMPLETED
48 participants
OBSERVATIONAL
Started: Jan 1, 2015
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03844074COMPLETEDPHASE3
61 participants
INTERVENTIONAL
Hurstville, Australia +8 more
Started: Oct 1, 2018
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753COMPLETEDPHASE3
228 participants
INTERVENTIONAL
Tucson, United States +49 more
Started: Jun 25, 2019
Single or Combined Protocols for NV-AMD
NCT03552770COMPLETEDPHASE4
109 participants
INTERVENTIONAL
Started: Nov 23, 2014
Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration
NCT01032109COMPLETEDNA
45 participants
INTERVENTIONAL
Kumamoto, Japan
Started: Oct 1, 2006
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348COMPLETEDPHASE4
500 participants
INTERVENTIONAL
Started: Nov 1, 2005
Bevacizumab for Neovascular Age-related Macular Degeneration
NCT01306591COMPLETEDNA
210 participants
INTERVENTIONAL
Beijing, China
Started: Jan 1, 2008
Showing 20 of 134 total trials